Shanghai MicroPort Endovascular MedTech Co., Ltd.

SHSE:688016 Rapport sur les actions

Capitalisation boursière : CN¥11.9b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shanghai MicroPort Endovascular MedTech Croissance future

Future contrôle des critères 5/6

Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 24% and 25% per annum respectively. EPS is expected to grow by 21.1% per annum. Return on equity is forecast to be 18.1% in 3 years.

Informations clés

24.0%

Taux de croissance des bénéfices

21.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices22.5%
Taux de croissance des recettes25.0%
Rendement futur des capitaux propres18.1%
Couverture par les analystes

Good

Dernière mise à jour03 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Aug 15
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

Jun 29
Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Apr 29
These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Apr 09
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Mar 25
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Prévisions de croissance des bénéfices et des revenus

SHSE:688016 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20262,5401,0715409777
12/31/20251,94680243976910
12/31/20241,53663543161110
3/31/20241,260552458651N/A
12/31/20231,187492368558N/A
9/30/20231,121444166398N/A
6/30/20231,05942122369N/A
3/31/2023924358-10308N/A
12/31/202289735740334N/A
9/30/2022839367133340N/A
6/30/2022781346276362N/A
3/31/2022745338242337N/A
12/31/2021685316211300N/A
9/30/2021652302248299N/A
6/30/2021618279255291N/A
3/31/2021569257239269N/A
12/31/2020470215191217N/A
9/30/2020414192148174N/A
6/30/2020377177142166N/A
3/31/2020341156133154N/A
12/31/2019334142122143N/A
9/30/2019306127117138N/A
6/30/201928211584117N/A
3/31/201925710390118N/A
12/31/20182319182107N/A
12/31/201716563N/A69N/A
12/31/201612541N/A30N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 688016's forecast earnings growth (24% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 688016's earnings (24% per year) are forecast to grow faster than the CN market (21.9% per year).

Croissance élevée des bénéfices: 688016's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 688016's revenue (25% per year) is forecast to grow faster than the CN market (13.4% per year).

Croissance élevée des revenus: 688016's revenue (25% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 688016's Return on Equity is forecast to be low in 3 years time (18.1%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y